Recombinant antigens
HBeAg
for Hepatitis B virus (HBV)
The “e” antigen (HBeAg) is formed by the pre-core protein ORF that will result in the secretion of a heterogeneous population of polypeptides that display “e” antigenicity.
During the replication cycle of hepatitis B virus (HBV), three major viral antigens, termed core antigen, surface antigen and “e” antigen, are produced. The core antigen is a conformational antigenic determinant displayed by the viral core protein, and the surface antigen represents the antigenic determinants displayed by the three viral envelope proteins. It has been used as the synonym for HBV envelope proteins. The core protein expressed this way will self assemble into core particles that display core antigenicity. In contrast, the expression of the pre-core protein ORF will result in the secretion of a heterogeneous population of polypeptides that display “e” antigenicity.
While HBeAg antigen has no demonstrated role in the viral replication cycle, the antigen has long been a key clinical marker for viral replication, infectivity, disease severity, and response to treatment.
- NAME
- Hbeag
- DESCRIPTION
- e antigen that comprises the 10 aa pre-core sequence plus the 149-residue assembly core domain
- GEN
- secuencia pre-núcleo más el dominio central
- PURITY
- >95% by observation on SDS-PAGE electrophoresis
- Formats
Liquid solution or dry powder (lyophilised) in vials of 0.1 mg*, 1 mg and bulk.
*under availability, for liquid format
* Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. In addition, we follow a rigorous quality control for each lot.
References of Recombinant antigen HBeAg
Folletos
- Rekom Biotech catalogue
- Recombinant proteins for in vitro diagnosis of human infectious diseases
- Sexually transmitted diseases (STD)
- IVD reagents for Transfusion-Transmitted Infectious diseases
Videos
Reagent sheet
- NAME
- HBeAg
- DESCRIPTION
- e antigen that comprises the 10 aa pre-core sequence plus the 149-residue assembly core domain
- PURITY
- >95% by observation on SDS-PAGE electrophoresis
- Formats
Liquid solution or dry powder (lyophilised) in vials of 0.1 mg*, 1 mg and bulk.
*under availability, for liquid format
* Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. In addition, we follow a rigorous quality control for each lot.